Amygdalar opioids modulate hypothalamic melanocortin-induced anorexia.
We wanted to assess the possibility that opioid activity in the central amygdala (CeA) could modulate the feeding inhibition of melanocortin stimulation of the paraventricular hypothalamus (PVN). The melanocortin system is important in both the acute regulation of satiety and feeding behavior and in the integration of long-term appetite signals. Melanotan II (MTII) is a synthetic MC3R and MC4R agonist which reduces food intake when given intracerebroventricularly (ICV) and into the PVN. Tyr-D-Ala-Gly-(me) Phe-Gly-ol (DAMGO), a micro-opioid receptor agonist, increases food intake, while opioid antagonists, like naltrexone (NTX), inhibit food intake after injection into many brain sites involved in appetite regulation, including the CeA. In food-deprived male Sprague-Dawley rats, co-injected intra-PVN MTII partially blocked the orexigenic effect of co-injected intra-CeA DAMGO. Intra-CeA NTX co-injected with intra-PVN MTII reduced food intake significantly more than either alone. NTX administered intra-CeA reduced c-Fos-immunoreactivity (IR) in nucleus accumbens neurons significantly compared to the intra-PVN MTII treated animals, animals co-injected intra-PVN with MTII and intra-CeA with NTX animals, and control animals. Intra-PVN MTII induced c-Fos-IR in significantly more PVN neurons than observed in control animals. Intra-CeA NTX co-injected with intra-PVN MTII induced c-Fos-IR significantly in PVN neurons relative to control and intra-CeA NTX animals. Such data support the significance of opioid action within the CeA as a modulator of the feeding regulation action of melanocortins within the PVN, occurring within the context of a larger appetitive network.
Beckman
Tiffany R
TR
Department of Medicine, University of Minnesota, Minneapolis, MN 55455, United States. beckm004@umn.edu
Shi
Qiuying
Q
Levine
Allen S
AS
Billington
Charles J
CJ
D000679:Amygdala / Q000187:drug effects / Q000378:metabolism*; D000701:Analgesics, Opioid / Q000378:metabolism*; D000818:Animals; D001069:Appetite Regulation / Q000187:drug effects / Q000502:physiology*; D004347:Drug Interactions; D004435:Eating / Q000187:drug effects / Q000502:physiology*; D020875:Enkephalin, Ala(2)-MePhe(4)-Gly(5)- / Q000494:pharmacology; D005508:Food Deprivation; D006728:Hormones / Q000494:pharmacology; D008297:Male; D053486:Melanocortins / Q000378:metabolism*; D009271:Naltrexone / Q000494:pharmacology; D009434:Neural Pathways / Q000502:physiology; D018377:Neurotransmitter Agents / Q000494:pharmacology; D010286:Paraventricular Hypothalamic Nucleus / Q000187:drug effects / Q000378:metabolism*; D010456:Peptides, Cyclic / Q000494:pharmacology; D051381:Rats; D017207:Rats, Sprague-Dawley; D044104:Receptor, Melanocortin, Type 3 / Q000187:drug effects / Q000378:metabolism; D044105:Receptor, Melanocortin, Type 4 / Q000187:drug effects / Q000378:metabolism; D017450:Receptors, Opioid, mu / Q000187:drug effects / Q000378:metabolism; D000521:alpha-MSH / Q000031:analogs & derivatives / Q000494:pharmacology
D000701:Analgesics, Opioid; D006728:Hormones; D053486:Melanocortins; D018377:Neurotransmitter Agents; D010456:Peptides, Cyclic; D044104:Receptor, Melanocortin, Type 3; D044105:Receptor, Melanocortin, Type 4; D017450:Receptors, Opioid, mu; D020875:Enkephalin, Ala(2)-MePhe(4)-Gly(5)-; C079282:melanotan-II; D000521:alpha-MSH; D009271:Naltrexone